Vir Biotechnology is a San Francisco-based commercial-stage immunology company developing therapies for serious infectious diseases and, more recently, oncology. It is best known for sotrovimab, a COVID-19 monoclonal antibody developed with GSK, and is advancing tobevibart + elebsiran for chronic hepatitis delta plus T-cell engager oncology assets licensed from Sanofi.
Vir Biotechnology is publicly traded
IPO'd on Oct 10, 2019
This company is no longer available on our private secondary market. Shares can be traded publicly under VIR.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2016
Employees
350–400
Total Funding
$300M
2 rounds
Announced global collaboration with Astellas for VIR-5500; closed Apr 2026 with $240M upfront cash plus $75M equity investment
Non-dilutive-heavy cash infusion extends runway into 2H28, lowering near-term financing risk
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Total raised $300M across 2 rounds
Last updated 10-01-2026
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| 2018 | Series B | $150M | — | SoftBank Vision Fund |
| Sep 26, 2017 | Series A | $150M | — | ARCH Venture Partners |
Marianne De Backer
President & Chief Executive Officer
Jason O'Byrne
EVP & Chief Financial Officer
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Moderna
mRNA platform biotech with infectious disease and oncology pipelines.
Regeneron Pharmaceuticals
Antibody-based therapeutics company; developed COVID-19 antibody cocktail competing with sotrovimab.
Arrowhead Pharmaceuticals
RNAi therapeutics developer with hepatitis B/D programs overlapping Vir's pipeline.
Gilead Sciences
Large antiviral pharma with HIV, hepatitis and oncology franchises.
Yes, Vir Biotechnology is publicly traded under the ticker symbol VIR on the NASDAQ. The company went public in Oct 10, 2019.
Vir Biotechnology trades under the ticker symbol VIR on the NASDAQ. It began trading in Oct 10, 2019.
Vir Biotechnology (VIR on the NASDAQ) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker VIR to place an order.
Vir Biotechnology went public in Oct 10, 2019 via ipo. Vir went public on NASDAQ (VIR) on October 10, 2019 at $20/share, raising ~$143M gross ($126.4M net) at a ~$2.2B valuation.
Vir Biotechnology raised $300M across 2 disclosed funding rounds prior to its public listing.
Vir Biotechnology is headquartered in San Francisco, CA.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.